Aurelia Caparrós Appointed as Chief Business Officer of Amarna Therapeutics

PRIVATEApr 19, 2024

Position

Chief Business Officer

Company

Amarna Therapeutics

Aurelia Caparrós

aurelia.caparros@amarnatherapeutics.com

LeidenManufacturingBiotechnologyHealth CareScience And EngineeringBiopharma

Description

Aurelia Caparrós has been appointed as the new Chief Business Officer (CBO) of Amarna Therapeutics, effective 1st of April 2024. Bringing more than 25 years of healthcare industry experience with expertise in business development, strategy, and global marketing, she will be responsible for driving Amarna's future growth and expansion both in the Netherlands and Spain, and her key responsibilities will include identifying assets, companies, and areas of interest, designing tailored partnering structures, and securing attractive deals through the entire deal-making process.

Other recent leadership changes in Science And Engineering and Biopharma

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Electra appoints Kellyn Blossom as Head of Communications and Policy in Washington, D.C. (May 1, 2024)
Co-Diagnostics, Inc. Appoints Richard Abbott as President and Announces Key Executive Appointments (April 4, 2024)
YS Biopharma Appoints Dave Chenn as Interim CEO and Hui Shao as Co-CEO and CBO (May 7, 2024)
Everest Medicines Appoints Sandra Zeng as Chief Medical Officer and Rico Liang as Chief Product Officer (March 18, 2024)
Olympus appoints Julien Sauvagnargues as President and CEO of Olympus Corporation of the Americas (April 19, 2024)
Verastem Oncology Appoints John Hayslip, M.D. as Chief Medical Officer (April 18, 2024)

Who to call at Amarna Therapeutics, and when

A new leader at Amarna Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Amarna Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Amarna Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Amarna Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Amarna Therapeutics

Location

Leiden, South Holland, Netherlands

About

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero) that for the first time makes it possible to produce SV40-derived vectors suitable for therapeutic use. The company's fully integrated gene therapy platform combining SuperVero with its genetically engineered SVec viral vector is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this 'natural' non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna's head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Amarna Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans